Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IPSEY IPSEN	$31.25 +2.3%	$29.65	$25.11 ▼ $32.25	$10.48B	0.53	743 shs	191 shs
ONC BeOne Medicines	$294.55 +1.4%	$249.71	$152.81 ▼ $300.00	$32.28B	0.28	440,809 shs	893,521 shs
SDZNY Sandoz Group	$56.94 +1.7%	$51.85	$35.61 ▼ $57.22	$25.05B	0.6	35,440 shs	22,137 shs
UCBJY UCB	$101.30 +0.4%	$93.61	$71.16 ▼ $106.60	N/A	0.51	44,062 shs	16,018 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IPSEY IPSEN	+2.32%	+1.73%	+3.80%	+21.27%	+2.86%
ONC BeOne Medicines	+4.01%	+14.59%	+14.27%	+25.70%	+29,034,999,900.00%
SDZNY Sandoz Group	-0.97%	0.00%	+7.71%	+39.17%	+43.85%
UCBJY UCB	+1.63%	-0.03%	+11.55%	+29.54%	+30.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IPSEY IPSEN	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	2.5622 of 5 stars	3.5	0.0	0.0	0.0	3.0	1.7	0.6
SDZNY Sandoz Group	1.7084 of 5 stars	0.0	5.0	0.8	0.0	0.0	0.0	2.5
UCBJY UCB	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IPSEY IPSEN	3.00	Buy	N/A	N/A
ONC BeOne Medicines	3.00	Buy	$327.56	11.21% Upside
SDZNY Sandoz Group	2.00	Hold	N/A	N/A
UCBJY UCB	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest IPSEY, UCBJY, ONC, and SDZNY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$321.00 ➝ $345.00
7/16/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$311.00 ➝ $349.00
7/16/2025	UCBJY UCB	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/27/2025	ONC BeOne Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$313.00 ➝ $330.00
6/27/2025	ONC BeOne Medicines	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$317.00 ➝ $321.00
6/27/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$311.00
5/8/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC BeOne Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
5/2/2025	SDZNY Sandoz Group	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Moderate Buy
4/28/2025	ONC BeOne Medicines	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$312.00 ➝ $312.00
4/24/2025	ONC BeOne Medicines	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$334.00 ➝ $334.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IPSEY IPSEN	$3.87B	2.71	N/A	N/A	N/A	∞
ONC BeOne Medicines	$3.81B	8.47	N/A	N/A	$34.10 per share	8.64
SDZNY Sandoz Group	$10.36B	2.42	$2.69 per share	21.16	$18.56 per share	3.07
UCBJY UCB	$6.66B	N/A	$4.03 per share	25.16	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IPSEY IPSEN	$374.30M	N/A	0.00	10.85	N/A	N/A	N/A	N/A	7/31/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	414.86	N/A	-9.40%	-7.55%	-4.42%	8/6/2025 (Confirmed)
SDZNY Sandoz Group	$1M	N/A	0.00	17.15	0.98	N/A	N/A	N/A	8/7/2025 (Estimated)
UCBJY UCB	$1.15B	N/A	0.00	23.56	0.66	N/A	N/A	N/A	7/23/2025 (Estimated)

Latest IPSEY, UCBJY, ONC, and SDZNY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IPSEY IPSEN	$0.25	0.80%	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
SDZNY Sandoz Group	$0.44	0.77%	N/A	N/A	N/A
UCBJY UCB	$0.48	0.47%	N/A	N/A	N/A

Latest IPSEY, UCBJY, ONC, and SDZNY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/3/2025	IPSEY IPSEN		$0.2896	0.97%	6/9/2025	6/10/2025	6/25/2025
4/21/2025	UCBJY UCB		$0.4838	0.62%	4/28/2025	4/29/2025	5/14/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IPSEY IPSEN	N/A	1.34	1.15
ONC BeOne Medicines	0.05	1.96	1.71
SDZNY Sandoz Group	0.57	1.24	0.79
UCBJY UCB	0.30	1.36	0.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IPSEY IPSEN	N/A
ONC BeOne Medicines	48.55%
SDZNY Sandoz Group	0.06%
UCBJY UCB	N/A

Insider Ownership

Company	Insider Ownership
IPSEY IPSEN	N/A
ONC BeOne Medicines	6.62%
SDZNY Sandoz Group	N/A
UCBJY UCB	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IPSEY IPSEN	5,358	335.26 million	N/A	Not Optionable
ONC BeOne Medicines	11,000	109.60 million	102.34 million	N/A
SDZNY Sandoz Group	23,406	440.00 million	N/A	Not Optionable
UCBJY UCB	9,378	N/A	N/A	Not Optionable

IPSEY, UCBJY, ONC, and SDZNY Headlines

Recent News About These Companies

UCB (OTCMKTS:UCBJY) Upgraded at The Goldman Sachs Group

July 18 at 2:13 AM | americanbankingnews.com

UCB (UCBJY) Upgraded to Strong Buy: What Does It Mean for the Stock?

July 16 at 6:22 AM | msn.com

UCB SA’s Growth Potential: Buy Rating on Bimzelx’s Transformative Impact

July 16 at 2:48 AM | tipranks.com

Here's What Could Help UCB (UCBJY) Maintain Its Recent Price ... - Nasdaq

July 11, 2025 | nasdaq.com

Here's What Could Help UCB (UCBJY) Maintain Its Recent Price Strength

July 9, 2025 | msn.com

TD Cowen maintains UCB stock Buy rating, EUR250 target

March 27, 2025 | uk.investing.com

UCB SA (UCBJY)

February 2, 2025 | finance.yahoo.com

UCB Announces U.S. Availability of 320 mg/2 mL Single-Injection Administration Option for BIMZELX® (bimekizumab-bkzx)

January 17, 2025 | finance.yahoo.com

UCB (OTC:UCBJY) Stock Quotes, Forecast and News Summary

November 22, 2024 | benzinga.com

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease

November 20, 2024 | benzinga.com

Biogen, UCB release phase 3 data on lupus candidate dapirolizumab

November 19, 2024 | msn.com

Oruka draws buy at Stifel on potential against psoriasis

October 11, 2024 | msn.com

UCB Presents New 4-year Data for BIMZELX® (bimekizumab-bkzx) in Moderate-to-Severe Plaque Psoriasis at EADV 2024

September 26, 2024 | finance.yahoo.com

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

September 24, 2024 | finance.yahoo.com

UCB gets expanded FDA approval for psoriasis drug Bimzelx

September 23, 2024 | seekingalpha.com

UCB United Community Banks, Inc.

August 29, 2024 | seekingalpha.com

Barclays Sticks to Its Buy Rating for UCB SA (0NZT)

August 27, 2024 | markets.businessinsider.com

Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies

August 26, 2024 | msn.com

DAY BY DAY Upgrades UCB SA - Depositary Receipt () (UCBJY)

August 12, 2024 | msn.com

Barclays Remains a Buy on UCB SA (0NZT)

July 29, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

D-Wave Is Rising Again Despite Dilution—What’s the Deal?
By Nathan Reiff | July 7, 2025
View D-Wave Is Rising Again Despite Dilution—What’s the Deal?
Palantir Gets Price Hike From Wedbush Amid High Valuation
By Chris Markoch | July 15, 2025
View Palantir Gets Price Hike From Wedbush Amid High Valuation
These 3 Dividend Stocks Are Not Concerned With Tariff Noise
By Thomas Hughes | July 11, 2025
View These 3 Dividend Stocks Are Not Concerned With Tariff Noise
IGM ETF: Expand Tech Exposure With Top AI Leaders
By Jeffrey Neal Johnson | July 1, 2025
View IGM ETF: Expand Tech Exposure With Top AI Leaders
MarketBeat Week in Review – 07/07 - 07/11
By MarketBeat Staff | July 12, 2025
View MarketBeat Week in Review – 07/07 - 07/11

IPSEY, UCBJY, ONC, and SDZNY Company Descriptions

IPSEN OTCMKTS:IPSEY

$31.25 +0.71 (+2.32%)

As of 07/17/2025 12:29 PM Eastern

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

BeOne Medicines NASDAQ:ONC

$294.55 +4.20 (+1.45%)

As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Sandoz Group OTCMKTS:SDZNY

$56.94 +0.94 (+1.68%)

As of 03:59 PM Eastern

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

UCB OTCMKTS:UCBJY

$101.30 +0.39 (+0.39%)

As of 03:58 PM Eastern

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time